• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS).

作者信息

Kashef Mohammed Amin, Giugliano Gregory

机构信息

Division of Cardiovascular Disease, Baystate Medical Center, Springfield, MA, USA.

Tufts University School of Medicine, Department of Medicine, Boston, MA, USA.

出版信息

Glob Cardiol Sci Pract. 2016 Dec 30;2016(4):e201635. doi: 10.21542/gcsp.2016.35.

DOI:10.21542/gcsp.2016.35
PMID:28979904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5624184/
Abstract
摘要

相似文献

1
Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS).他汀类药物的遗留效应：苏格兰西部冠心病预防研究（WOSCOPS）的20年随访
Glob Cardiol Sci Pract. 2016 Dec 30;2016(4):e201635. doi: 10.21542/gcsp.2016.35.
2
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.苏格兰西部冠心病预防研究：高危人群的识别及与其他心血管干预试验的比较。
Lancet. 1996 Nov 16;348(9038):1339-42.
3
Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.苏格兰西部冠心病预防研究中的筛查经历及基线特征。WOSCOPS研究小组。苏格兰西部冠心病预防研究。
Am J Cardiol. 1995 Sep 1;76(7):485-91. doi: 10.1016/s0002-9149(99)80135-0.
4
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.男性原发性低密度脂蛋白胆固醇水平升高至 190mg/dL 或以上的心血管疾病一级预防中降低低密度脂蛋白胆固醇：来自 WOSCOPS（苏格兰西部冠状动脉预防研究）5 年随机试验和 20 年观察随访的分析。
Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6.
5
Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.西苏格兰冠心病预防研究（WOSCOPS）的临床和经济研究结果能否推广至其他人群？比利时的一个案例研究。WOSCOPS经济分析小组。
Acta Cardiol. 2000 Aug;55(4):239-46. doi: 10.2143/AC.55.4.2005746.
6
Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.一级预防中降脂治疗的经济学：来自苏格兰西部冠心病预防研究的经验教训。
Am J Cardiol. 2001 Mar 8;87(5A):19B-22B. doi: 10.1016/s0002-9149(01)01451-5.
7
Letter by Koh Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".Koh 就文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防的低密度脂蛋白胆固醇降低：来自WOSCOPS（苏格兰西部冠心病预防研究）5年随机试验和20年观察性随访的分析》所写的信
Circulation. 2018 May 29;137(22):2417-2418. doi: 10.1161/CIRCULATIONAHA.117.033136.
8
Letter by Löwe et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".洛维等人就文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防中的低密度脂蛋白胆固醇降低：西苏格兰冠心病预防研究（WOSCOPS）5年随机试验及20年观察性随访分析》所写的信
Circulation. 2018 May 29;137(22):2415-2416. doi: 10.1161/CIRCULATIONAHA.117.032213.
9
Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up".瓦列霍 - 瓦斯等人对关于文章《低密度脂蛋白胆固醇水平原发性升高至190mg/dL及以上男性心血管疾病一级预防的低密度脂蛋白胆固醇降低治疗：西苏格兰冠心病预防研究（WOSCOPS）5年随机试验及20年观察性随访分析》的信件的回应
Circulation. 2018 May 29;137(22):2419-2420. doi: 10.1161/CIRCULATIONAHA.118.033781.
10
The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).心血管事件减少工具（CERT）——一种基于苏格兰西部冠心病预防研究（WOSCOPS）开发的简化心脏风险预测模型。
Am J Cardiol. 2000 Mar 15;85(6):720-4. doi: 10.1016/s0002-9149(99)00847-4.

引用本文的文献

1
Association between statin discontinuation after proprotein convertase subtilisin/kexin type 9 inhibitor initiation and subsequent atherosclerotic cardiovascular disease events.前蛋白转化酶枯草溶菌素/克新9型抑制剂起始治疗后他汀类药物停药与随后的动脉粥样硬化性心血管疾病事件之间的关联。
J Manag Care Spec Pharm. 2025 Apr;31(4):377-385. doi: 10.18553/jmcp.2025.31.4.377.
2
Distinct roles of size-defined HDL subpopulations in cardiovascular disease.大小明确的高密度脂蛋白亚群在心血管疾病中的不同作用。
Curr Opin Lipidol. 2025 Jun 1;36(3):111-118. doi: 10.1097/MOL.0000000000000959. Epub 2024 Oct 25.
3
Potential for advances in data linkage and data science to support injury prevention research.

本文引用的文献

1
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.依洛尤单抗与依折麦布治疗肌肉相关他汀类药物不耐受患者的疗效和耐受性：GAUSS-3 随机临床试验。
JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608.
2
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.在高危受试者中使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂进行进一步心血管结局研究的原理与设计。
Am Heart J. 2016 Mar;173:94-101. doi: 10.1016/j.ahj.2015.11.015. Epub 2015 Dec 17.
3
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
数据链接和数据科学在支持伤害预防研究方面的潜在进展。
Inj Prev. 2024 Nov 21;30(6):442-445. doi: 10.1136/ip-2024-045367.
4
Direct binding to sterols accelerates endoplasmic reticulum-associated degradation of HMG CoA reductase.直接与固醇结合可加速 HMG CoA 还原酶的内质网相关降解。
Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2318822121. doi: 10.1073/pnas.2318822121. Epub 2024 Feb 6.
5
Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group).墨西哥患者的风险分层与血脂评估，REMECAR中血脂与心血管分析的证据。墨西哥心血管疾病注册研究（REMECAR组）。
Atheroscler Plus. 2022 Aug 28;50:32-39. doi: 10.1016/j.athplu.2022.08.002. eCollection 2022 Dec.
6
Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom.确定心血管疾病一级预防的最佳策略：对英国成本效益分析的系统评价
Health Technol Assess. 2022 Dec 9. doi: 10.3310/QOVK6659.
7
Undertreatment or Overtreatment With Statins: Where Are We?他汀类药物治疗不足或过度治疗：我们目前的状况如何？
Front Cardiovasc Med. 2022 Apr 29;9:808712. doi: 10.3389/fcvm.2022.808712. eCollection 2022.
8
Effect of Individual Nutrition Therapy and Exercise Regime on Gait Speed, Physical Function, Strength and Balance, Body Composition, Energy and Protein, in Injured, Vulnerable Elderly: A Multisite Randomized Controlled Trial (INTERACTIVE).个体营养治疗和运动方案对受伤、脆弱老年人的步速、身体功能、力量和平衡、身体成分、能量和蛋白质的影响：多中心随机对照试验（INTERACTIVE）。
Nutrients. 2021 Sep 13;13(9):3182. doi: 10.3390/nu13093182.
9
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.在血脂异常的糖尿病患者中，贝特类药物附加治疗的遗留效应：ACCORDION 研究的二次分析。
Cardiovasc Diabetol. 2020 Mar 5;19(1):28. doi: 10.1186/s12933-020-01002-x.
10
[Primary prevention of coronary heart disease : Evidence-based drug treatment].冠心病的一级预防：循证药物治疗
Herz. 2020 Feb;45(1):39-49. doi: 10.1007/s00059-019-04873-3.
他汀类药物治疗降低低密度脂蛋白胆固醇的长期安全性和有效性：西苏格兰冠心病预防研究的20年随访
Circulation. 2016 Mar 15;133(11):1073-80. doi: 10.1161/CIRCULATIONAHA.115.019014. Epub 2016 Feb 10.
4
Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.通过抑制前蛋白转化酶枯草溶菌素9实现动脉粥样硬化稳定：心血管预防的一个不断发展的概念。
Atherosclerosis. 2015 Dec;243(2):593-7. doi: 10.1016/j.atherosclerosis.2015.10.023. Epub 2015 Oct 23.
5
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.前蛋白转化酶枯草溶菌素 9 抑制：降低心血管疾病风险的新治疗机制。
Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080.
6
New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory.需要新的指标来直观呈现早期低密度脂蛋白胆固醇（LDL-C）降低对心血管疾病发展轨迹的长期影响。
Vascul Pharmacol. 2015 Aug;71:37-9. doi: 10.1016/j.vph.2015.03.008. Epub 2015 Apr 16.
7
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.他汀类药物相关肌肉症状：对他汀类药物治疗的影响——欧洲动脉粥样硬化学会关于评估、病因及管理的共识专家组声明
Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18.
8
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.依洛尤单抗治疗血脂异常的 52 周安慰剂对照试验。
N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.
9
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南：美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
10
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.他汀类药物治疗对医疗资源利用的长期影响及其在心血管疾病一级预防中的成本效益：一项基于记录链接的研究。
Eur Heart J. 2014 Feb;35(5):290-8. doi: 10.1093/eurheartj/eht232. Epub 2013 Jul 9.